
Cardior Pharmaceuticals Demonstrates Reversal of Cardiac Hypertrophy by H19 Gene Therapy
Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure D…
Administration of AAV9 expressing H19 attenuates cardiac hypertrophy in vivo and prevents progression to heart failure D…
Die Promega GmbH, Mannheim, hat die GloResponse™ NFAT-RE-luc2P HEK293-Zelllinie und die GloResponse™ CRE-luc2P HEK293-Ze…